There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monash IVF Group Ltd (AU:MVF – Research Report), Genetic Signatures Ltd. (AU:GSS – Research Report) and Impedimed Limited (IPDQF – Research Report) with bullish sentiments.
Monash IVF Group Ltd (AU:MVF)
In a report released yesterday, Jonathon Higgins from Shaw and Partners maintained a Buy rating on Monash IVF Group Ltd, with a price target of A$1.50. The company’s shares closed last Friday at A$1.17.
Higgins has an average return of
According to TipRanks.com, Higgins is ranked #6942 out of 8374 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monash IVF Group Ltd with an A$1.40 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Genetic Signatures Ltd. (AU:GSS)
Taylor Collison analyst Dennis Hulme maintained a Buy rating on Genetic Signatures Ltd. on May 3 and set a price target of A$2.21. The company’s shares closed last Friday at A$0.68.
According to TipRanks.com, Hulme is ranked #6962 out of 8374 analysts.
Currently, the analyst consensus on Genetic Signatures Ltd. is a Moderate Buy with an average price target of A$1.58.
Impedimed Limited (IPDQF)
In a report issued on May 5, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Impedimed Limited, with a price target of A$0.18. The company’s shares closed last Tuesday at $0.12, close to its 52-week high of $0.13.
Shapiro has an average return of
According to TipRanks.com, Shapiro is ranked #4660 out of 8374 analysts.
Currently, the analyst consensus on Impedimed Limited is a Strong Buy with an average price target of $0.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
